| | 特定对象调研 分析师会议 √ □ | | --- | --- | | 投资者关系 | 媒体采访 业绩说明会 □ □ | | | 新闻发布会 路演活动 □ □ | | 活动类别 | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位 | 国信证券组织的投资者 | | 时间 | 2026 年 1 月 11 日 | | 地点 | 进门财经电话会议 | | 上市公司接 | 副总裁、首席信息官 吴维严 | | | 副总裁、董事会秘书 陶钧 | | 待人员姓名 | 医策科技 王晓梅 CEO | | | 公司管理层对投资者提问的回复情况如下： | | | 1．AI 对医疗行业是否带来结构性重塑？ | | | 答：将推动医疗健康应用快速发展，尤其在基层医疗与健康 | | | 管理场景。但复杂病症与循证医学领域的 AI 应用仍需高质量多 | | | 模态数据支撑。患者端将受益于全生命周期健康管理；在医生端， | | | AI 主要作为辅助工具，助力经验知识平民化。迪安通过"临床科 | | 投资者关系 | 研+基层赋能"闭环推动产品落地。 | | 活动主要内 | 【风险提示：目前公司的 AI ...

Group 1: Current Development Trends - The company has gradually cleared goodwill and interference from COVID-19 related reports, laying a foundation for future growth [1] - The industry is accelerating the exit of "small and scattered" enterprises, entering a critical period for leading companies [1] - Despite pressures from policies like DRG and centralized procurement, the company is transforming its organizational, business, and product structures [1] Group 2: Five-Year Strategic Plan and Progress - The company aims to enhance internal management and focus on high-quality development, achieving over 25% reduction in procurement costs and 16% and 29% decreases in management and financial expenses respectively [2] - Core technology competitiveness in blood, neuroimmunology, and pathology has been strengthened, with pathogen tNGS, liquid biopsy, and tumor companion diagnostics growing by 35%, 22%, and 20% respectively [2] - The proportion of special testing revenue in diagnostic service revenue has increased to 47.63%, up by 7.32 percentage points from the end of 2024 [2] Group 3: Customer and Market Expansion - The company signed 1,036 new clients in the first half of 2025, with 133 being tertiary hospitals, increasing the revenue share from tertiary hospitals to 49.28% [2] - Cumulative cooperative clients exceed 800, with nearly 100 precision centers established [2] - The company is actively exploring international markets, with Vietnam's lab receiving ISO 15189 certification [2] Group 4: Financial Performance and Cash Flow - Accounts receivable reached 5.383 billion yuan, with a provision of 215 million yuan, indicating an expected improvement in cash flow management [4] - Operating cash flow improved to 278 million yuan, a 199.56% increase compared to the same period in 2024 [4] Group 5: Service and Product Innovations - The company has launched a digital product matrix including data, AI+CDSS, AI+health management, and AI+CRO, with revenue from digital products surpassing the total for the previous year [9] - The gross profit margin for services increased by 0.8 percentage points to 33.12%, attributed to strategic adjustments and optimization of customer structure [10] Group 6: Industry Challenges and Responses - The impact of the Jiangsu province tumor gene testing centralized procurement policy is expected to lower prices significantly, but the company anticipates long-term growth due to its integrated advantages [11] - The company is transitioning from traditional hospital collaborations to a networked service system, enhancing service offerings from diagnosis to full lifecycle management [12] Group 7: Data Utilization and Future Plans - The company has accumulated over 20 PB of data, with annual increments of approximately 1.5 PB, which will be utilized for AI model training and clinical decision support [14] - Future plans include expanding data services and operational management through clinical specialty databases and intelligent inspection platforms [14]